Apyx Medical (NASDAQ:APYX) Announces Earnings Results

Apyx Medical (NASDAQ:APYX) issued its earnings results on Thursday. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01, FiscalAI reports. The company had revenue of $13.88 million for the quarter, compared to the consensus estimate of $13.18 million. Apyx Medical had a negative net margin of 14.78% and a negative return on equity of 76.18%.

Here are the key takeaways from Apyx Medical’s conference call:

• Second-quarter revenue rose 22% to $13.9 million, led by a 28% increase in surgical aesthetics sales to $12.4 million. Management attributed the growth to AYON adoption, higher international generator sales, and increased domestic single-use handpiece volume.
• AYON received FDA clearance for power-assisted liposuction, with initial shipments beginning in June and a broader commercial launch planned for the third quarter. Management said early surgeon feedback was “exceptional” and expects more than 95% of new AYON customers to include the PowerLipo attachment.
• Management highlighted clinical studies supporting Renuvion’s role in body contouring, including higher patient satisfaction and fewer abdominoplasty or revision procedures when combined with liposuction, while maintaining comparable complication rates.
• Profitability improved, with gross margin rising to 63.9%, operating loss narrowing to $1.8 million, and adjusted EBITDA loss improving to $0.7 million. However, operating cash use increased to $3.5 million, and the company ended the quarter with $27.6 million in cash.
• The company reaffirmed 2026 revenue guidance of $59 million to $60 million and expects OEM revenue to decline to approximately $5 million from $7.5 million in 2025. Tariffs are also pressuring margins, although potential tariff refunds are not included in current guidance.

Apyx Medical Trading Down 2.6%

APYX stock traded down $0.11 during mid-day trading on Friday, hitting $4.05. 299,178 shares of the company were exchanged, compared to its average volume of 64,993. The company has a quick ratio of 4.79, a current ratio of 5.80 and a debt-to-equity ratio of 2.68. The firm has a market capitalization of $169.74 million, a P/E ratio of -20.25 and a beta of 1.39. The business has a fifty day simple moving average of $4.24 and a 200-day simple moving average of $3.94. Apyx Medical has a 12-month low of $1.70 and a 12-month high of $5.08.

Analyst Ratings Changes

A number of analysts have recently issued reports on APYX shares. Wall Street Zen downgraded shares of Apyx Medical from a “buy” rating to a “hold” rating in a report on Sunday, April 26th. HC Wainwright started coverage on Apyx Medical in a research report on Monday, July 13th. They issued a “buy” rating and a $7.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Apyx Medical in a research note on Wednesday, June 24th. Finally, Zacks Research raised Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $6.60.

Hedge Funds Weigh In On Apyx Medical

Large investors have recently made changes to their positions in the stock. Citadel Advisors LLC acquired a new position in Apyx Medical during the third quarter worth $28,000. Osaic Holdings Inc. acquired a new stake in shares of Apyx Medical in the second quarter valued at $50,000. Franklin Resources Inc. purchased a new stake in shares of Apyx Medical in the 3rd quarter valued at $59,000. Hudson Bay Capital Management LP purchased a new stake in shares of Apyx Medical in the 4th quarter valued at $73,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in Apyx Medical during the 4th quarter worth about $111,000. 55.33% of the stock is currently owned by institutional investors and hedge funds.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.